IBDEI0AP ; ; 13-FEB-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 13, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,14193,1,1,0)
 ;;=1^446.6
 ;;^UTILITY(U,$J,358.3,14193,1,8,0)
 ;;=8^Thrombotic Thrombocytopenic Purpura (TTP)
 ;;^UTILITY(U,$J,358.3,14193,2)
 ;;=^119061
 ;;^UTILITY(U,$J,358.3,14194,0)
 ;;=451.9^^93^846^8
 ;;^UTILITY(U,$J,358.3,14194,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14194,1,1,0)
 ;;=1^451.9
 ;;^UTILITY(U,$J,358.3,14194,1,8,0)
 ;;=8^Thrombophlebitis
 ;;^UTILITY(U,$J,358.3,14194,2)
 ;;=^93357
 ;;^UTILITY(U,$J,358.3,14195,0)
 ;;=287.5^^93^846^6
 ;;^UTILITY(U,$J,358.3,14195,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14195,1,1,0)
 ;;=1^287.5
 ;;^UTILITY(U,$J,358.3,14195,1,8,0)
 ;;=8^Thrombocytopenia Nos
 ;;^UTILITY(U,$J,358.3,14195,2)
 ;;=^118988
 ;;^UTILITY(U,$J,358.3,14196,0)
 ;;=287.1^^93^846^5
 ;;^UTILITY(U,$J,358.3,14196,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14196,1,1,0)
 ;;=1^287.1
 ;;^UTILITY(U,$J,358.3,14196,1,8,0)
 ;;=8^Qualitative Platelet Defects
 ;;^UTILITY(U,$J,358.3,14196,2)
 ;;=^101922
 ;;^UTILITY(U,$J,358.3,14197,0)
 ;;=287.30^^93^846^4
 ;;^UTILITY(U,$J,358.3,14197,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14197,1,1,0)
 ;;=1^287.30
 ;;^UTILITY(U,$J,358.3,14197,1,8,0)
 ;;=8^Primary Thrombocytopenia (ITP)
 ;;^UTILITY(U,$J,358.3,14197,2)
 ;;=^332841
 ;;^UTILITY(U,$J,358.3,14198,0)
 ;;=238.71^^93^846^7
 ;;^UTILITY(U,$J,358.3,14198,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14198,1,1,0)
 ;;=1^238.71
 ;;^UTILITY(U,$J,358.3,14198,1,8,0)
 ;;=8^Thrombocytosis,Essential
 ;;^UTILITY(U,$J,358.3,14198,2)
 ;;=^334027
 ;;^UTILITY(U,$J,358.3,14199,0)
 ;;=286.0^^93^846^1
 ;;^UTILITY(U,$J,358.3,14199,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14199,1,1,0)
 ;;=1^286.0
 ;;^UTILITY(U,$J,358.3,14199,1,8,0)
 ;;=8^Congenital Factor VIII
 ;;^UTILITY(U,$J,358.3,14199,2)
 ;;=^27454
 ;;^UTILITY(U,$J,358.3,14200,0)
 ;;=275.03^^93^846^3
 ;;^UTILITY(U,$J,358.3,14200,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14200,1,1,0)
 ;;=1^275.03
 ;;^UTILITY(U,$J,358.3,14200,1,8,0)
 ;;=8^Hemochromatosis NEC
 ;;^UTILITY(U,$J,358.3,14200,2)
 ;;=^339604
 ;;^UTILITY(U,$J,358.3,14201,0)
 ;;=205.00^^93^847^1
 ;;^UTILITY(U,$J,358.3,14201,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14201,1,1,0)
 ;;=1^205.00
 ;;^UTILITY(U,$J,358.3,14201,1,8,0)
 ;;=8^A M L, W/O Remission
 ;;^UTILITY(U,$J,358.3,14201,2)
 ;;=^267531
 ;;^UTILITY(U,$J,358.3,14202,0)
 ;;=205.01^^93^847^2
 ;;^UTILITY(U,$J,358.3,14202,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14202,1,1,0)
 ;;=1^205.01
 ;;^UTILITY(U,$J,358.3,14202,1,8,0)
 ;;=8^A M L,In Remission
 ;;^UTILITY(U,$J,358.3,14202,2)
 ;;=^267532
 ;;^UTILITY(U,$J,358.3,14203,0)
 ;;=205.10^^93^847^4
 ;;^UTILITY(U,$J,358.3,14203,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14203,1,1,0)
 ;;=1^205.10
 ;;^UTILITY(U,$J,358.3,14203,1,8,0)
 ;;=8^C M L,W/O Remission
 ;;^UTILITY(U,$J,358.3,14203,2)
 ;;=^267533
 ;;^UTILITY(U,$J,358.3,14204,0)
 ;;=205.11^^93^847^3
 ;;^UTILITY(U,$J,358.3,14204,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14204,1,1,0)
 ;;=1^205.11
 ;;^UTILITY(U,$J,358.3,14204,1,8,0)
 ;;=8^C M L,In Remission
 ;;^UTILITY(U,$J,358.3,14204,2)
 ;;=^267534
 ;;^UTILITY(U,$J,358.3,14205,0)
 ;;=289.0^^93^847^7
 ;;^UTILITY(U,$J,358.3,14205,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14205,1,1,0)
 ;;=1^289.0
 ;;^UTILITY(U,$J,358.3,14205,1,8,0)
 ;;=8^Secondary Polycythemia
 ;;^UTILITY(U,$J,358.3,14205,2)
 ;;=^186856
 ;;^UTILITY(U,$J,358.3,14206,0)
 ;;=238.4^^93^847^6
 ;;^UTILITY(U,$J,358.3,14206,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14206,1,1,0)
 ;;=1^238.4
 ;;^UTILITY(U,$J,358.3,14206,1,8,0)
 ;;=8^Polycythemia Rubra Vera
 ;;^UTILITY(U,$J,358.3,14206,2)
 ;;=^96105
 ;;^UTILITY(U,$J,358.3,14207,0)
 ;;=288.9^^93^847^9
 ;;^UTILITY(U,$J,358.3,14207,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14207,1,1,0)
 ;;=1^288.9
 ;;^UTILITY(U,$J,358.3,14207,1,8,0)
 ;;=8^Unspecified Dis Of W B C
 ;;^UTILITY(U,$J,358.3,14207,2)
 ;;=^267993
 ;;^UTILITY(U,$J,358.3,14208,0)
 ;;=289.81^^93^847^8
 ;;^UTILITY(U,$J,358.3,14208,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14208,1,1,0)
 ;;=1^289.81
 ;;^UTILITY(U,$J,358.3,14208,1,8,0)
 ;;=8^Unspecified Blood Diseases
 ;;^UTILITY(U,$J,358.3,14208,2)
 ;;=^329886
 ;;^UTILITY(U,$J,358.3,14209,0)
 ;;=238.75^^93^847^5
 ;;^UTILITY(U,$J,358.3,14209,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14209,1,1,0)
 ;;=1^238.75
 ;;^UTILITY(U,$J,358.3,14209,1,8,0)
 ;;=8^Myelodysplastic Syndrome
 ;;^UTILITY(U,$J,358.3,14209,2)
 ;;=^334031
 ;;^UTILITY(U,$J,358.3,14210,0)
 ;;=204.00^^93^848^2
 ;;^UTILITY(U,$J,358.3,14210,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14210,1,1,0)
 ;;=1^204.00
 ;;^UTILITY(U,$J,358.3,14210,1,8,0)
 ;;=8^A L L,W/O Remission
 ;;^UTILITY(U,$J,358.3,14210,2)
 ;;=^267521
 ;;^UTILITY(U,$J,358.3,14211,0)
 ;;=204.01^^93^848^1
 ;;^UTILITY(U,$J,358.3,14211,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14211,1,1,0)
 ;;=1^204.01
 ;;^UTILITY(U,$J,358.3,14211,1,8,0)
 ;;=8^A L L, In Remission
 ;;^UTILITY(U,$J,358.3,14211,2)
 ;;=^267522
 ;;^UTILITY(U,$J,358.3,14212,0)
 ;;=204.10^^93^848^5
 ;;^UTILITY(U,$J,358.3,14212,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14212,1,1,0)
 ;;=1^204.10
 ;;^UTILITY(U,$J,358.3,14212,1,8,0)
 ;;=8^C L L,W/O Remission
 ;;^UTILITY(U,$J,358.3,14212,2)
 ;;=^267523
 ;;^UTILITY(U,$J,358.3,14213,0)
 ;;=204.11^^93^848^4
 ;;^UTILITY(U,$J,358.3,14213,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14213,1,1,0)
 ;;=1^204.11
 ;;^UTILITY(U,$J,358.3,14213,1,8,0)
 ;;=8^C L L,In Remission
 ;;^UTILITY(U,$J,358.3,14213,2)
 ;;=^267524
 ;;^UTILITY(U,$J,358.3,14214,0)
 ;;=201.90^^93^848^8
 ;;^UTILITY(U,$J,358.3,14214,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14214,1,1,0)
 ;;=1^201.90
 ;;^UTILITY(U,$J,358.3,14214,1,8,0)
 ;;=8^Hodgkins Lymphoma,Unspec Type
 ;;^UTILITY(U,$J,358.3,14214,2)
 ;;=^267430
 ;;^UTILITY(U,$J,358.3,14215,0)
 ;;=202.00^^93^848^14
 ;;^UTILITY(U,$J,358.3,14215,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14215,1,1,0)
 ;;=1^202.00
 ;;^UTILITY(U,$J,358.3,14215,1,8,0)
 ;;=8^Lymphoma, Low-Grade (Nodular)
 ;;^UTILITY(U,$J,358.3,14215,2)
 ;;=^72606
 ;;^UTILITY(U,$J,358.3,14216,0)
 ;;=200.20^^93^848^15
 ;;^UTILITY(U,$J,358.3,14216,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14216,1,1,0)
 ;;=1^200.20
 ;;^UTILITY(U,$J,358.3,14216,1,8,0)
 ;;=8^Lymphoma,Burkitts
 ;;^UTILITY(U,$J,358.3,14216,2)
 ;;=^17529
 ;;^UTILITY(U,$J,358.3,14217,0)
 ;;=202.10^^93^848^23
 ;;^UTILITY(U,$J,358.3,14217,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14217,1,1,0)
 ;;=1^202.10
 ;;^UTILITY(U,$J,358.3,14217,1,8,0)
 ;;=8^Mycosis Fungoides
 ;;^UTILITY(U,$J,358.3,14217,2)
 ;;=^80360
 ;;^UTILITY(U,$J,358.3,14218,0)
 ;;=273.3^^93^848^19
 ;;^UTILITY(U,$J,358.3,14218,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14218,1,1,0)
 ;;=1^273.3
 ;;^UTILITY(U,$J,358.3,14218,1,8,0)
 ;;=8^Macroglobulinemia
 ;;^UTILITY(U,$J,358.3,14218,2)
 ;;=^73013
 ;;^UTILITY(U,$J,358.3,14219,0)
 ;;=203.00^^93^848^22
 ;;^UTILITY(U,$J,358.3,14219,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14219,1,1,0)
 ;;=1^203.00
 ;;^UTILITY(U,$J,358.3,14219,1,8,0)
 ;;=8^Multiple Myeloma,W/O Remission
 ;;^UTILITY(U,$J,358.3,14219,2)
 ;;=^267514
 ;;^UTILITY(U,$J,358.3,14220,0)
 ;;=203.01^^93^848^21
 ;;^UTILITY(U,$J,358.3,14220,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14220,1,1,0)
 ;;=1^203.01
 ;;^UTILITY(U,$J,358.3,14220,1,8,0)
 ;;=8^Multiple Myeloma,In Remission
 ;;^UTILITY(U,$J,358.3,14220,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,14221,0)
 ;;=202.40^^93^848^7
 ;;^UTILITY(U,$J,358.3,14221,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14221,1,1,0)
 ;;=1^202.40
 ;;^UTILITY(U,$J,358.3,14221,1,8,0)
 ;;=8^Hairy-Cell Leukemia
 ;;^UTILITY(U,$J,358.3,14221,2)
 ;;=^69587
 ;;^UTILITY(U,$J,358.3,14222,0)
 ;;=200.10^^93^848^17
 ;;^UTILITY(U,$J,358.3,14222,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14222,1,1,0)
 ;;=1^200.10
 ;;^UTILITY(U,$J,358.3,14222,1,8,0)
 ;;=8^Lymphoma,Int/High (Diffuse)
 ;;^UTILITY(U,$J,358.3,14222,2)
 ;;=^175886
 ;;^UTILITY(U,$J,358.3,14223,0)
 ;;=273.1^^93^848^20
 ;;^UTILITY(U,$J,358.3,14223,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14223,1,1,0)
 ;;=1^273.1
 ;;^UTILITY(U,$J,358.3,14223,1,8,0)
 ;;=8^Monoclon Paraproteinemia
 ;;^UTILITY(U,$J,358.3,14223,2)
 ;;=^78888
 ;;^UTILITY(U,$J,358.3,14224,0)
 ;;=238.79^^93^848^18
 ;;^UTILITY(U,$J,358.3,14224,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14224,1,1,0)
 ;;=1^238.79
 ;;^UTILITY(U,$J,358.3,14224,1,8,0)
 ;;=8^Lymphoproliferat Dis
 ;;^UTILITY(U,$J,358.3,14224,2)
 ;;=^334033
 ;;^UTILITY(U,$J,358.3,14225,0)
 ;;=202.90^^93^848^16
 ;;^UTILITY(U,$J,358.3,14225,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14225,1,1,0)
 ;;=1^202.90
 ;;^UTILITY(U,$J,358.3,14225,1,8,0)
 ;;=8^Lymphoma,Diffuse,Unspec Site
 ;;^UTILITY(U,$J,358.3,14225,2)
 ;;=^267504
 ;;^UTILITY(U,$J,358.3,14226,0)
 ;;=205.01^^93^848^3
 ;;^UTILITY(U,$J,358.3,14226,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14226,1,1,0)
 ;;=1^205.01
 ;;^UTILITY(U,$J,358.3,14226,1,8,0)
 ;;=8^A M L, in Remission
 ;;^UTILITY(U,$J,358.3,14226,2)
 ;;=^267532
 ;;^UTILITY(U,$J,358.3,14227,0)
 ;;=205.11^^93^848^6
 ;;^UTILITY(U,$J,358.3,14227,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14227,1,1,0)
 ;;=1^205.11
 ;;^UTILITY(U,$J,358.3,14227,1,8,0)
 ;;=8^C M L, in Remission
 ;;^UTILITY(U,$J,358.3,14227,2)
 ;;=^267534
 ;;^UTILITY(U,$J,358.3,14228,0)
 ;;=201.40^^93^848^9
 ;;^UTILITY(U,$J,358.3,14228,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14228,1,1,0)
 ;;=1^201.40
 ;;^UTILITY(U,$J,358.3,14228,1,8,0)
 ;;=8^Hodgkins-Ltmph-Histio
 ;;^UTILITY(U,$J,358.3,14228,2)
 ;;=^265549
 ;;^UTILITY(U,$J,358.3,14229,0)
 ;;=201.70^^93^848^10
 ;;^UTILITY(U,$J,358.3,14229,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14229,1,1,0)
 ;;=1^201.70
 ;;^UTILITY(U,$J,358.3,14229,1,8,0)
 ;;=8^Hodgkins-Lymphocytic Dep
 ;;^UTILITY(U,$J,358.3,14229,2)
 ;;=^265553
 ;;^UTILITY(U,$J,358.3,14230,0)
 ;;=201.60^^93^848^11
 ;;^UTILITY(U,$J,358.3,14230,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14230,1,1,0)
 ;;=1^201.60
 ;;^UTILITY(U,$J,358.3,14230,1,8,0)
 ;;=8^Hodgkins-Mixed Cell
